DZ Bank has increased its price target for Fresenius Medical Care from 46 EUR to 50 EUR, maintaining a 'Buy' rating. This adjustment is due to a reduced risk discount, influenced by US midterm election outcomes and government stance on kidney treatment, despite slightly lowered 2027 estimates.
DZ Bank's analyst Sven Kürten raised the fair value target for Fresenius Medical Care (FME) from 46 EUR to 50 EUR, while keeping a 'Buy' rating. This positive adjustment stems from a reduction in the risk discount applied to the company, primarily attributed to the outcome of US midterm elections and the US government's position on kidney disease treatment. While the third-quarter performance was slightly better than expected, the analyst also noted a decrease in estimates for 2027, which introduces a slight long-term caution despite the immediate positive price target. For traders, this indicates a short-term positive sentiment for FME due to the analyst's endorsement and reduced perceived risk, but the lowered 2027 estimates suggest potential headwinds or a more conservative long-term outlook that warrants monitoring.